Related Experiment Videos
A Metabo-Reprogramming Niche Remodeling System Halts Osteoarthritis by Restoring the FGF21-Arginine Axis
Hao Pan1,2, Haoze Zhu1, Siman Huang1
1Department of Orthopaedic Surgery, Department of Wound Healing, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Abstract:
Osteoarthritis (OA), a global leading cause of chronic pain and disability, lacks disease-modifying osteoarthritis drugs (DMOADs) targeting its core pathogenesis. scRNA-seq of human OA cartilage showed marked depletion of a high-arginine-metabolism chondrocyte subpopulation driving cartilage degeneration, with its key upstream regulator FGF21, significantly downregulated in OA cartilage. Mechanistically, FGF21 rescues IL-1β-induced chondrocyte dysfunction via ASS1/ASL -mediated arginine biosynthesis, an effect abrogated by ASS1 knockdown, confirming the FGF21-arginine pathway's role and FGF21 as a therapeutic target. Guided by this mechanism, we engineered a hydrogel-based bioinspired metabo-reprogramming niche remodeling system (MetaRemod) to achieve precise and efficient delivery of FGF21 to OA chondrocytes. In a mouse OA model, MetaRemod effectively halted OA progression by sustaining targeted delivery of bioactive FGF21, restoring chondrocyte arginine metabolism, preserving cartilage structure and joint space, restoring subchondral bone integrity, and mitigating synovitis. Critically, scRNA-seq of treated cartilage confirmed the restoration of the depleted "high-arginine-metabolism" chondrocyte subpopulation, directly validating that MetaRemod reverses OA's core metabolic defect. This study establishes the FGF21-arginine metabolic axis as a key therapeutic target for OA and validates MetaRemod as a promising strategy that synergizes targeted FGF21 delivery and metabolic reprogramming, laying a solid foundation for the clinical translation of metabolic reprogramming-based DMOADs.
Insights
Researchers identified a key metabolic pathway involving FGF21 and arginine in osteoarthritis (OA). They developed a novel treatment (MetaRemod) that restores this pathway, effectively halting OA progression and preserving joint health in mice.
Area of Science:
- Biochemistry
- Regenerative Medicine
- Orthopedics
Background:
- Osteoarthritis (OA) is a leading cause of chronic pain and disability, with no current treatments targeting its core pathogenesis.
- A specific chondrocyte subpopulation crucial for cartilage health is depleted in OA, linked to reduced levels of Fibroblast Growth Factor 21 (FGF21).
Purpose of the Study:
- To investigate the role of the FGF21-arginine metabolic axis in OA pathogenesis.
- To develop and evaluate a novel drug delivery system (MetaRemod) for targeted FGF21 delivery to reprogram chondrocyte metabolism and treat OA.
Main Methods:
- Single-cell RNA sequencing (scRNA-seq) of human OA cartilage to identify key cellular and molecular changes.
- Mechanistic studies elucidating the FGF21-arginine biosynthesis pathway in chondrocytes.
- Development of a hydrogel-based system (MetaRemod) for localized FGF21 delivery.
- Preclinical evaluation of MetaRemod in a mouse model of OA.
Main Results:
- scRNA-seq revealed a depleted chondrocyte subpopulation with high arginine metabolism in OA, associated with downregulated FGF21.
- FGF21 was found to rescue chondrocyte dysfunction by promoting arginine biosynthesis via the ASS1/ASL pathway.
- MetaRemod effectively delivered FGF21 in a mouse OA model, restoring chondrocyte metabolism, preserving cartilage and subchondral bone, and reducing synovitis.
- Treated cartilage showed restoration of the depleted high-arginine-metabolism chondrocyte subpopulation, confirming metabolic defect reversal.
Conclusions:
- The FGF21-arginine metabolic axis is a critical therapeutic target for osteoarthritis.
- MetaRemod, a bioinspired niche remodeling system, demonstrates a promising strategy for OA treatment by synergizing targeted FGF21 delivery and metabolic reprogramming.
- This approach provides a strong foundation for the clinical translation of metabolic reprogramming-based disease-modifying osteoarthritis drugs (DMOADs).
Related Concept Videos
Osteoclasts in Bone Remodeling
Bone Remodeling and Repair
Bone Remodeling
TGF - β Signaling Pathway
Bone Formation by Endochondral Ossification